Sionna Therapeutics, Inc. (SION) Financial Statements
Free cash flow over the same period: -$76.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SIONSionna Therapeutics, Inc.Follow SION — free
—
Price chart with a free account
- Market cap
- 162.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 57.3 | 60.3 | 72.0 | |
| Operating income | -70.6 | -89.0 | -109.5 | |
| Pre-tax income | -61.7 | -75.3 | -97.4 | |
| Income tax | — | 0.0 | — | |
| Net income | -61.7 | -75.3 | -97.4 | |
| Diluted EPS ($) | -15.99 | -1.88 | -2.17 | |
| Diluted shares (mn) | 3.9 | 40.0 | — |
USD millions · SEC XBRL
Sionna Therapeutics, Inc. — questions
- What is Sionna Therapeutics, Inc.'s net income?
- -$97.4M over the twelve months to 2026-06-30.
- What is Sionna Therapeutics, Inc.'s free cash flow?
- -$76.2M over the twelve months to 2026-06-30.
- What are Sionna Therapeutics, Inc.'s diluted earnings per share?
- $-2.17 over the twelve months to 2026-06-30.
Every figure on this page comes from Sionna Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.